Glucosamine sulfate suppresses the expressions of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis

Clinica Chimica Acta

Volumn 372, Issue 1-2, 2006, Pages 167-172

  Chu, Shu Chen ^a   Yang, Shun Fa ^b   Lue, Ko Huang ^b   Hsieh, Yih Shou ^b   Lee, Ching Yi ^b   Chou, Ming Chih ^b   Lu, Ko Hsiu ^b,c  

^a CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Glucosamine sulfate; Inhibitor; Matrix metalloproteinase 2, 9; Osteoarthritis; Plasminogen activator

Indexed keywords

GELATIN; GELATINASE; GELATINASE A; GELATINASE B; GLUCOSAMINE SULFATE; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; VIARTRIL S;

ARTICLE; ARTICULAR CARTILAGE; CELL CULTURE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; KNEE MENISCUS; OSTEOARTHRITIS; PRIORITY JOURNAL; SYNOVIAL FLUID; ZYMOGRAPHY;

ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GELATINASES; GLUCOSAMINE; HUMANS; OSTEOARTHRITIS; URINARY PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 33747819617     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.04.014     Document Type: Article

References (39)

1. Pelletier J.P., Martel-Pelletier J., and Howell D.S. Etiopathogenesis of osteoarthritis. In: Koopman W.J. (Ed). Arthritis and allied conditions: a textbook of rheumatology. 14th ed. (2000), Williams & Wilkins, Baltimore 2195-2245
2. Pincus T. Clinical evidence for osteoarthritis as an inflammatory disease. Curr Rheumatol Rep 3 (2001) 524-534
3. Lu K.H., Yang S.F., Chu S.C., Chen P.N., Chou M.C., Hsiao T.Y., et al. The significance of altered expressions of gelatinases in the synovium of patient with arthritic effusions. Clin Rheumatol 23 (2004) 21-26
4. Chu S.C., Yang S.F., Lue K.H., Hsiao T.Y., Hsieh Y.S., and Lu K.H. The clinical significance of gelatinase B in gouty arthritis of the knee. Clin Chim Acta 339 (2004) 77-83
5. Chu S.C., Yang S.F., Lue K.H., Hsieh Y.S., Lin Z.I., and Lu K.H. Gelatinases in septic arthritis of the native and replaced knee. Clin Orthop 427 (2004) 179-183
6. Hsieh Y.S., Yang S.F., Chu S.C., Chen P.N., Chou M.C., Hsu M.C., et al. Expression changes of gelatinases in human osteoarthritic knees and arthroscopic débridement. Arthroscopy 20 (2004) 482-488
7. Chu S.C., Yang S.F., Lue K.H., Hsieh Y.S., Wu C.L., and Lu K.H. Regulation of gelatinases expression by cytokines, endotoxins and pharmacological agents in the human osteoarthritic knee. Connect Tissue Res 45 (2004) 142-150
8. Irigoyen J.P., Munoz-Canoves P., Montero L., Koziczak M., and Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56 (1999) 104-132
9. Daci E., Udagawa N., Martin T.J., Bouillon R., and Carmeliet G. The role of the plasminogen system in bone resorption in vitro. J Bone Miner Res 14 (1999) 946-952
10. Mazzieri R., Masiero L., Zanetta L., Monea S., Onisto M., Garbisa S., et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16 (1997) 2319-2332
11. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., French D.L., and Quigley J.P. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274 (1999) 13066-13076
12. Andreasen P.A., Georg B., Lund L.R., Riccio A., and Stacey S.N. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 88 (1990) 1-19
13. Martel-Pelletier J., Faure M.P., McCollum R., Mineau F., Cloutier J.M., and Pelletier J.P. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. J Biol Chem 18 (1991) 1863-1871
14. Kikuchi H., Tanaka S., and Matsuo O. Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 14 (1987) 439-445
15. Matsuo O., Tanaka S., and Kikuchi H. Effect of urinary trypsin inhibitor on osteoarthritis. Thromb Res 52 (1988) 237-245
16. Chu S.C., Yang S.F., Lue K.H., Hsieh Y.S., Hsiao T.Y., and Lu K.H. Urokinase-type plasminogen activator, receptor and inhibitor correlating with gelatinase-B (MMP-9) contributes to the inflammation in gouty arthritis of the knee. J Rheumatol 33 (2006) 311-317
17. Hsieh Y.S., Yang S.F., Lue K.H., and Lu K.H. Clinical correlation with the PA/plasmin system in septic arthritis of the knee. Clin Orthop 16 (2006) [online]
18. McAlindon T.E., LaValley M.P., Gulin J.P., and Felson D.T. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283 (2000) 1469-1475
19. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357 (2001) 251-256
20. Towheed T.E., Maxwell L., Anastassiades T.P., Shea B., Houpt J., Robinson V., et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 18 (2005) CD002946
21. Bassleer C., Rovati L., and Franchimont P. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 6 (1998) 427-434
22. Gouze J.N., Bordji K., Gulberti S., Terlain B., Netter P., Magdalou J., et al. Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. Arthritis Rheum 44 (2001) 351-360
23. 2 in articular cartilage explants. Osteoarthritis Cartilage 13 (2005) 387-394
24. Hua J., Sakamoto K., and Nagaoka I. Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leukoc Bio 71 (2002) 632-640
25. Piperno M., Reboul P., Hellio Le Graverand M.P., Peschard M.J., Annefeld M., et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage 8 (2000) 207-212
26. Kleiner D.E., and Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218 (1994) 325-329
27. Makowski G.S., and Ramsby M.L. Calibrating gelatin zymograms with human gelatinase standards. Anal Biochem 236 (1996) 353-356
28. Lequesne M., Brandt K., Bellamy N., Moskowitz R., Menkes C.J., Pelletier J.P., et al. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol Suppl 41 (1994) 65-71 [discussion 72-3]
29. Persiani S., Roda E., Rovati L.C., Locatelli M., Giacovelli G., and Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 13 (2005) 1041-1049
30. Altman R.D., Hochberg M.C., Moskowitz R.W., and Schnitzer T.J. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 43 (2000) 1905-1915
31. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 82 (1999) 259-270
32. Busso N., Peclat V., So A., and Sappino AP. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 56 (1997) 550-557
33. Cheras P.A., Whitaker A.N., Blackwell E.A., Sinton T.J., Chapman M.D., and Peacock K.A. Hypercoagulability and hypofibrinolysis in primary osteoarthritis. Clin Orthop 334 (1997) 57-67
34. Pelletier J.P., Mineau F., Fernandes J., Kiansa K., Ranger P., and Martel-Pelletier J. Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts. Clin Exp Rheumatol 15 (1997) 393-398
35. Hamilton J.A., Campbell I.K., Wojta J., and Cheung D. Plasminogen activators and their inhibitors in arthritic disease. Ann N Y Acad Sci 667 (1992) 87-100
36. Muller-Fassbender H., Bach G.L., Haase W., Rovati L.C., and Setnikar I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 2 (1994) 51-59
37. Dodge G.R., and Jimenez S.A. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 11 (2003) 424-432
38. Towheed T.E., and Anastassiades T.P. Glucosamine therapy for osteoarthritis. J Rheumatol 26 (1999) 2294-2297
39. Bruyere O., Pavelka K., Rovati L.C., Deroisy R., Olejarova M., Gatterova J., et al. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause 11 (2004) 138-143